QL1706 (iparomlimab + tuvonralimab) with TACE and lenvatinib for second-line treatment of unresectable intermediate-to-advanced liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-arm, single-center Phase 2 trial gives participants the combined antibody QL1706 (iparomlimab plus tuvonralimab) together with transarterial chemoembolization (TACE) and oral lenvatinib as second-line therapy for unresectable intermediate-to-advanced hepatocellular carcinoma. The protocol includes screening, a treatment period with scheduled QL1706 dosing plus TACE and continuous lenvatinib, and a follow-up phase for efficacy and safety monitoring. Eligible patients must have failed or been intolerant to first-line PD-1/PD-L1 inhibitor plus bevacizumab and have at least one measurable lesion per RECIST v1.1. Tumor response, progression-free and overall survival, and adverse events will be recorded throughout the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Comprehension and voluntary signing of the study's informed consent form;
* Age ≥18 years, any gender;
* Histologically or clinically confirmed hepatocellular carcinoma;
* Documented failure or intolerance to first-line therapy with PD-1/PD-L1 inhibitor plus bevacizumab;
* ECOG performance status 0-2;
* Child-Pugh class A or class B (score ≤7) without hepatic encephalopathy history;
* Life expectancy ≥3 months;
* At least one measurable target lesion confirmed by screening imaging per RECIST v1.1;
* Adequate organ and bone marrow function within 7 days prior to initial study treatment;
* Active HBV/HCV infection requires ongoing antiviral therapy; k.Fertile patients must use highly effective contraception with partners during treatment and ≥180 days post-last dose.

  2.Exclusion Criteria:
* Inability to comply with the study protocol or procedures;
* Histologically/cytologically confirmed fibrolamellar HCC, sarcomatoid HCC, cholangiocarcinoma, or mixed hepatocellular-cholangiocarcinoma;
* History of liver transplantation or planned transplantation;
* Presence of central nervous system metastases and/or leptomeningeal carcinomatosis;
* Baseline imaging showing Vp4 portal vein tumor thrombosis;
* Hypersensitivity to any study drug components or history of severe allergic reactions;
* Concurrent HBV and HCV co-infection;
* Clinically significant ascites requiring intervention during screening;
* Concurrent use of other investigational drugs or participation in another clinical trial within 4 weeks prior to enrollment;
* Esophageal/gastric variceal bleeding due to portal hypertension within 6 months before treatment initiation, or high-risk varices on endoscopy within 3 months;
* Current interstitial lung disease (ILD), history of steroid-required ILD, or other pulmonary fibrosis/organizing pneumonia affecting immune-related pulmonary toxicity assessment;
* Uncontrolled hypertension (SBP≥160 mmHg and/or DBP≥100 mmHg despite medication), coronary artery disease, arrhythmias, or heart failure (NYHA Class ≥II);
* Uncontrolled clinically significant infections requiring IV antimicrobial therapy;
* Proteinuria ≥2+ (≥1.0g/24h);
* History of hemorrhagic tendency regardless of severity within 2 months prior to enrollment;
* Arterial/venous thromboembolic events within 12 months before treatment initiation (e.g., cerebrovascular accident including TIA);
* Acute myocardial infarction, acute coronary syndrome, or CABG within 6 months before treatment;
* Unhealed fractures or chronic non-healing wounds;
* Coagulopathy, bleeding diathesis, or current therapeutic anticoagulation;
* Other malignancies within 5 years except curatively resected basal/squamous cell skin carcinoma or cervical carcinoma in situ;
* Active autoimmune disease or autoimmune disease history requiring immunosuppression within 4 weeks prior to enrollment;
* Prior allogeneic bone marrow or solid organ transplantation;
* Investigator assessment of ineligibility based on medical/safety reasons.

Where it's running

• Tianjin Medical University Cancer Institute and Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: Tongguo Si, Doctor
• Email: 18526812877@163.com
• Phone: +86 18526812877

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cryoablation with liver-directed immunotherapy and targeted therapy for melanoma liver metastases

  This trial tests a combination therapy including cryoablation, hepatic artery delivery of QL1706, intravenous dacarbazine, and oral lenvatinib to treat liver metastases from malignant melanoma in adults.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07847359

• Iparomlimab and Tuvonralimab with SBRT and Lenvatinib for Potentially Resectable Intermediate-Stage HCC

  This trial tests whether adding two antibodies together with SBRT and lenvatinib can improve outcomes for adults with potentially resectable intermediate-stage hepatocellular carcinoma.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07801287

• Iparomlimab and Tuvonralimab with Lenvatinib, Radiotherapy, and HAIC in HCC with PVTT

  This trial tests a multi-drug approach to see if it can control liver cancer that has grown into the portal vein in adults.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07776080

• Cryoablation with lenvatinib and QL1706 for advanced intrahepatic cholangiocarcinoma

  We will try freezing tumors (cryoablation) together with the drugs lenvatinib and QL1706 in people whose advanced intrahepatic cholangiocarcinoma has worsened after first-line treatment.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07070700

• Pre-surgery treatment with iparomlimab, tuvonralimab, and lenvatinib for liver cancer

  This trial will try a 9-week pre-surgery combination of two immune antibodies (iparomlimab and tuvonralimab) plus daily lenvatinib in people with resectable hepatocellular carcinoma who are at high risk of recurrence.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07014150

• Combining sintilimab, lenvatinib, and HAIC for treating borderline resectable liver cancer before surgery

  This study is testing if a combination of three treatments can help people with borderline resectable liver cancer do better in surgery compared to having surgery right away.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06904014

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.